MX367478B - Tratamiento de enfermedades colestasicas intrahepaticas. - Google Patents

Tratamiento de enfermedades colestasicas intrahepaticas.

Info

Publication number
MX367478B
MX367478B MX2016012203A MX2016012203A MX367478B MX 367478 B MX367478 B MX 367478B MX 2016012203 A MX2016012203 A MX 2016012203A MX 2016012203 A MX2016012203 A MX 2016012203A MX 367478 B MX367478 B MX 367478B
Authority
MX
Mexico
Prior art keywords
treatment
intrahepatic
diseases
cholestic
mbx
Prior art date
Application number
MX2016012203A
Other languages
English (en)
Other versions
MX2016012203A (es
Inventor
A Mcwherter Charles
Boudes Pol
Original Assignee
Cymaby Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymaby Therapeutics Inc filed Critical Cymaby Therapeutics Inc
Publication of MX2016012203A publication Critical patent/MX2016012203A/es
Publication of MX367478B publication Critical patent/MX367478B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporciona un tratamiento de enfermedades colestásicas intrahepáticas por medio de terapia con MBX-8025 o una sal de MBX-8025.
MX2016012203A 2014-03-20 2015-03-19 Tratamiento de enfermedades colestasicas intrahepaticas. MX367478B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461968037P 2014-03-20 2014-03-20
PCT/US2015/021502 WO2015143178A1 (en) 2014-03-20 2015-03-19 Treatment of intrahepatic cholestatic diseases

Publications (2)

Publication Number Publication Date
MX2016012203A MX2016012203A (es) 2017-01-19
MX367478B true MX367478B (es) 2019-08-23

Family

ID=52808186

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012203A MX367478B (es) 2014-03-20 2015-03-19 Tratamiento de enfermedades colestasicas intrahepaticas.

Country Status (32)

Country Link
US (5) US9486428B2 (es)
EP (1) EP3119384B1 (es)
JP (1) JP6568577B2 (es)
KR (1) KR102000332B1 (es)
CN (1) CN106102734B (es)
AU (1) AU2015231232B2 (es)
BR (1) BR112016020260A8 (es)
CA (1) CA2941401C (es)
CL (1) CL2016002338A1 (es)
CY (1) CY1120927T1 (es)
DK (1) DK3119384T3 (es)
EA (1) EA032358B1 (es)
ES (1) ES2701094T3 (es)
FI (1) FIC20253004I1 (es)
FR (1) FR25C1031I2 (es)
HR (1) HRP20181914T1 (es)
HU (2) HUE041733T2 (es)
IL (1) IL247920B (es)
LT (2) LT3119384T (es)
MX (1) MX367478B (es)
NL (1) NL301338I2 (es)
NO (1) NO2025035I1 (es)
NZ (1) NZ724057A (es)
PH (1) PH12016501769A1 (es)
PL (1) PL3119384T3 (es)
PT (1) PT3119384T (es)
RS (1) RS57970B1 (es)
SI (1) SI3119384T1 (es)
SM (1) SMT201800690T1 (es)
UA (1) UA120756C2 (es)
WO (1) WO2015143178A1 (es)
ZA (1) ZA201606043B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5694941B2 (ja) 2008-10-17 2015-04-01 シーマベイ セラピューティクス，インコーポレイティド 小型高密度ｌｄｌ粒子を減少させる方法
US10272058B2 (en) * 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CA2944139C (en) 2014-04-11 2020-11-03 Cymabay Therapeutics, Inc. Treatment of nafld and nash
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
JP7023371B2 (ja) * 2017-09-26 2022-02-21 サイマベイ・セラピューティクス・インコーポレイテッド 胆汁うっ滞性そう痒の処置
WO2020102351A1 (en) * 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
US12318357B2 (en) 2019-08-02 2025-06-03 Acelot, Inc. Small molecule drugs and related methods for treatment of diseases related to TDP-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation
US20210145774A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
WO2021097034A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
RS65546B1 (sr) 2021-02-01 2024-06-28 Cymabay Therapeutics Inc Tretman holangiopatija sa seladelparom

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
DE69636160D1 (de) 1995-03-06 2006-06-29 Isis Pharmaceuticals Inc Verfahren zur synthese von 2'-0-substituierten pyrimidinen und oligomere davon
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
DK0882061T3 (da) 1996-02-14 2004-09-27 Isis Pharmaceuticals Inc Sukkermodificerede gapped oligonukleotider
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) * 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
UA87467C2 (xx) 2003-09-19 2009-07-27 Янссен Фармацевтика Н.В 4-((феноксіалкіл)тіо)феноксіоцтова кислота та її аналоги$4-((феноксиалкил)тио)феноксиуксусная кислота и ее аналоги
PT1725234E (pt) 2004-03-05 2013-03-04 Univ Pennsylvania Métodos com efeitos secundários reduzidos para tratamento de patologias ou doenças associadas a hiperlipidemia e hipercolesterolemia
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
JP5694941B2 (ja) 2008-10-17 2015-04-01 シーマベイ セラピューティクス，インコーポレイティド 小型高密度ｌｄｌ粒子を減少させる方法
SG183529A1 (en) 2010-03-30 2012-10-30 Novartis Ag Uses of dgat1 inhibitors
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
HK1224186A1 (zh) 2013-11-20 2017-08-18 Cymabay Therapeutics, Inc. 纯阖家族型高胆固醇血症的治疗
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CA2944139C (en) 2014-04-11 2020-11-03 Cymabay Therapeutics, Inc. Treatment of nafld and nash
CN106470675A (zh) 2014-06-26 2017-03-01 西玛贝医药公司 严重高甘油三酯血症的治疗
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
JP7023371B2 (ja) 2017-09-26 2022-02-21 サイマベイ・セラピューティクス・インコーポレイテッド 胆汁うっ滞性そう痒の処置
WO2020102351A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
MX2021005724A (es) 2018-11-16 2021-07-21 Cymabay Therapeutics Inc Tratamiento combinado contra nafld y nash.

Also Published As

Publication number Publication date
CL2016002338A1 (es) 2017-04-21
US20170014363A1 (en) 2017-01-19
CY1120927T1 (el) 2019-12-11
US9486428B2 (en) 2016-11-08
CA2941401A1 (en) 2015-09-24
FR25C1031I2 (fr) 2026-03-27
AU2015231232B2 (en) 2018-08-02
BR112016020260A8 (pt) 2021-06-29
HUE041733T2 (hu) 2019-05-28
ZA201606043B (en) 2018-05-30
US20190192459A1 (en) 2019-06-27
US20150265560A1 (en) 2015-09-24
NO2025035I1 (no) 2025-08-01
UA120756C2 (uk) 2020-02-10
ES2701094T3 (es) 2019-02-20
WO2015143178A1 (en) 2015-09-24
HRP20181914T1 (hr) 2019-01-11
BR112016020260A2 (pt) 2017-08-15
KR20160125424A (ko) 2016-10-31
US20180036268A1 (en) 2018-02-08
JP6568577B2 (ja) 2019-08-28
AU2015231232A1 (en) 2016-09-22
LTPA2025529I1 (es) 2025-08-25
FIC20253004I1 (fi) 2025-07-31
EP3119384B1 (en) 2018-09-12
LT3119384T (lt) 2018-11-26
NZ724057A (en) 2018-09-28
US10828273B2 (en) 2020-11-10
HUS2500033I1 (hu) 2025-09-28
CN106102734B (zh) 2019-05-14
US20210023031A1 (en) 2021-01-28
FR25C1031I1 (fr) 2025-09-26
US11406611B2 (en) 2022-08-09
NL301338I2 (nl) 2025-09-11
RS57970B1 (sr) 2019-01-31
KR102000332B1 (ko) 2019-07-15
PT3119384T (pt) 2018-12-12
PH12016501769B1 (en) 2017-01-09
SI3119384T1 (sl) 2018-12-31
CN106102734A (zh) 2016-11-09
US9808436B2 (en) 2017-11-07
JP2017508817A (ja) 2017-03-30
DK3119384T3 (en) 2018-12-03
PH12016501769A1 (en) 2017-01-09
US10220011B2 (en) 2019-03-05
SMT201800690T1 (it) 2019-01-11
CA2941401C (en) 2019-06-11
IL247920B (en) 2019-03-31
MX2016012203A (es) 2017-01-19
PL3119384T3 (pl) 2019-03-29
EA032358B1 (ru) 2019-05-31
EP3119384A1 (en) 2017-01-25
EA201691887A1 (ru) 2017-03-31

Similar Documents

Publication Publication Date Title
MX2020007273A (es) Tratamiento del prurito colestasico.
MX2016012203A (es) Tratamiento de enfermedades colestasicas intrahepaticas.
IL283561B (en) Methods for treating ocular diseases
MX369921B (es) Tratamiento de la hgna y ehna.
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
IL249065A0 (en) Combination therapies for the treatment of cancer
DK3450553T3 (da) Mrna-terapi til behandling af øjensygdomme
PL3212174T3 (pl) Sposoby leczenia zakażeń wirusem filoviridae
EP3448263A4 (en) ELECTROTHERAPEUTIC TREATMENT
ECSP17015977A (es) Terapia de combinacion
LT3556775T (lt) Anti-lag-3 antikūnai, skirti hematologinių piktybinių susirgimų gydymui
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
EP3186010A4 (en) IMMERSIVE SHOWER HEAD
MX2018014915A (es) Tratamiento de enfermedades colestasicas intrahepaticas.
HUE053744T2 (hu) A rák kombinált kezelése
HUE053443T2 (hu) Heteroaril vegyületek szembetegségek kezelésére
FI20145484A7 (fi) Anodiliejun hydrometallurginen käsittely
DK2897382T3 (da) Forbedring af binaural kilde
SI3188599T1 (sl) Zdravljenje na osnovi anamorelina
IL246558A0 (en) Novel methods for treating cancer
DK3151814T3 (da) Behandling af en hudlæsion
PL3160913T3 (pl) Sposób oczyszczania osadu biologicznego
DK3182980T3 (da) Behandling af glykosyleringsmangelsygdomme
GB201410407D0 (en) Treatment of chagas disease
DK2975004T3 (da) Syrespildevandsbehandling

Legal Events

Date Code Title Description
FG Grant or registration